Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) Equity Average (2018 - 2025)

VYNE Therapeutics' Equity Average history spans 8 years, with the latest figure at $33.3 million for Q4 2025.

  • For Q4 2025, Equity Average fell 42.36% year-over-year to $33.3 million; the TTM value through Dec 2025 reached $33.3 million, down 42.36%, while the annual FY2025 figure was $39.9 million, 43.3% down from the prior year.
  • Equity Average reached $33.3 million in Q4 2025 per VYNE's latest filing, down from $41.5 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $86.1 million in Q1 2024 to a low of $14.4 million in Q3 2023.
  • Average Equity Average over 5 years is $51.8 million, with a median of $52.0 million recorded in 2022.
  • Peak YoY movement for Equity Average: plummeted 67.46% in 2023, then soared 380.96% in 2024.
  • A 5-year view of Equity Average shows it stood at $53.8 million in 2021, then tumbled by 33.71% to $35.6 million in 2022, then surged by 40.65% to $50.1 million in 2023, then grew by 15.35% to $57.8 million in 2024, then plummeted by 42.36% to $33.3 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Equity Average are $33.3 million (Q4 2025), $41.5 million (Q2 2025), and $48.1 million (Q1 2025).